Synopsis Migraine is a neurobiological disorder that affects around 960 million people worldwide and deters the quality of life. Despite the availability of a wide range of acute treatment options for migraines, including analgesics, non-steroidal anti-inflammatory drugs, etc. patients remain dissatisfied with their effects. In the present study, rimegepant, a calcitonin gene-related peptide receptor antagonist, is tested for efficacy and safety in the acute treatment of migraine.
This ‘ Med Fact ’ discusses the study- “ Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomized, phase 3, double-blind, placebo-controlled trial ”, from The Lancet . Authors : Robert Croop, Peter J Goodsby, David A Stock, et al. What was the need for the study? Patients with mild to severe intensity migraines often do not get complete…
